COMP <GO>
KRYS vs JNJ // REVENUE GROWTH (YOY)
Krystal Biotech Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: KRYS 5
— JNJ 8
▲ REVENUE GROWTH (YOY) LEADER: KRYS
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
revenue-growth
33.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 25.50% | -9.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | 18.5x | +34.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 2.97% | -1.00 | JNJ | /fcf-yield <GO> |
| Operating Margin | 41.50% | 34.70% | +6.80 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 28.50% | +24.10 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 33.90% | 6.00% | +27.90 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | KRYS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 60.4 | -6.57 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.08 | -0.17 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 23.0x | +16.40 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $662.49B | -$652.89B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | JNJ REV | KRYS GROSS % | JNJ GROSS % | KRYS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $94.19B | 44.0% | 67.9% | $188.9M | $19.70B |
| FY 2024 | $290.5M | $88.82B | 44.0% | 69.1% | $119.2M | $19.84B |
| FY 2023 | $50.7M | $85.16B | 44.0% | 44.0% | -$91.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
JNJ // BETA 1.08